Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology · 2025
Motor evoked potentials as a side effect biomarker for deep brain stimulation.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Testini Paola, Wang Austin, Cole Eric R, Miocinovic Svjetlana
Аннотация
OBJECTIVES: To determine if motor evoked potentials (MEP) - stimulation-induced muscle activation measured using electromyography - can serve as a biomarker of corticobulbar (CBT) and corticospinal (CST) tract activation induced by deep brain stimulation (DBS).
METHODS: In 12 patients with Parkinson's disease and subthalamic (n = 10) or pallidal (n = 2) DBS, contact mapping determined clinical motor side effect thresholds. For equivalent stimulation parameters (except lower frequency), EMG was recorded from cranial and arm muscles to determine the presence, peak amplitudes and latencies of MEP. Clinical side effect and MEP thresholds were compared and accuracy metrics calculated.
RESULTS: The MEP amplitudes increased with stimulation intensity. Latencies were shorter for cranial muscles, which were also more likely to generate an MEP. Clinical side effect and MEP thresholds were significantly correlated (R2 = 0.31; p = 0.0006), although most MEP thresholds were lower than side effect thresholds. The MEP accuracy in predicting side effects was 0.72, with a sensitivity of 0.68 and a specificity of 0.73.
CONCLUSIONS: MEP thresholds correlated with side effect thresholds but were often lower indicating subclinical CBT/CST activations.
SIGNIFICANCE: This study characterizes motor potentials evoked by DBS and demonstrates their potential utility as an objective biomarker for motor side effect detection during DBS programming.
METHODS: In 12 patients with Parkinson's disease and subthalamic (n = 10) or pallidal (n = 2) DBS, contact mapping determined clinical motor side effect thresholds. For equivalent stimulation parameters (except lower frequency), EMG was recorded from cranial and arm muscles to determine the presence, peak amplitudes and latencies of MEP. Clinical side effect and MEP thresholds were compared and accuracy metrics calculated.
RESULTS: The MEP amplitudes increased with stimulation intensity. Latencies were shorter for cranial muscles, which were also more likely to generate an MEP. Clinical side effect and MEP thresholds were significantly correlated (R2 = 0.31; p = 0.0006), although most MEP thresholds were lower than side effect thresholds. The MEP accuracy in predicting side effects was 0.72, with a sensitivity of 0.68 and a specificity of 0.73.
CONCLUSIONS: MEP thresholds correlated with side effect thresholds but were often lower indicating subclinical CBT/CST activations.
SIGNIFICANCE: This study characterizes motor potentials evoked by DBS and demonstrates their potential utility as an objective biomarker for motor side effect detection during DBS programming.